הריון וסרוקסט

לפני כשנה וחצי ילדתי ולאחר הלידה התחלתי לקחת סרוקסט (1.5ביום) אני רוצה להכנס להריון שוב וחשוב לי לדעת האם יש איזשהוא סיכון או בעיה עם נטילת סרוקסט בהיריון. כמו"כ השפעת הסרוקסט אחרי הלידה (לעניין הנקה וכו')

בדקי את הקישור הבא : http://www.yourhealthbase.com/breast_cancer_risk_factors.html More on breast cancer AND paroxetine TORONTO, CANADA. In the August 2000 issue of IHN we reported on the findings of Dr. Michelle Cotterchio AND colleagues (New England Journal of Medicine, Vol. 342, June 29, 2000, p. 2003) to the effect that the use of the antidepressant paroxetine (Paxil) may increase the risk of breast cancer by a factor of seven. If confirmed these findings would almost certainly lead to a caution against prescribing paroxetine to women. Not surprisingly, Dr. Cotterchio’s report has caused a considerable stir within the medical AND pharmaceutical communities. The December issue of the American Journal of Epidemiology contains two letters (one from the manufacturer of paroxetine, SmithKline Beecham Pharmaceuticals) that question the validity of Dr. Cotterchio’s conclusions. The authors of both letters point out that the number of cases of possible paroxetine-related breast cancer was small (9 cases AND 1 control) AND the SmithKline Beecham letter also makes the observation that most of the patients who had taken paroxetine had previously been exposed to fluoxetine (Prozac). Dr. Cotterchio replies that her report concluded that “use of paroxetine may be associated with a substantial increase in breast cancer” AND that future studies would be required in order to confirm this. She also reiterates that, while she AND her team do not suggest that paroxetine is a carcinogen (cancer initiator), they do believe that it could well be a promoter of breast cancer. She points out that animal studies support the hypothesis that antidepressants may be tumor promoters. It would seem that the final conclusion on the possible relationship between paroxetine AND breast cancer must await the completion of the larger study. Antidepressant medication use AND breast cancer risk. American Journal of Epidemiology, Vol. 152, December 1, 2000, pp. 1104-05 (letters to the editor) Antidepressants AND breast cancer TORONTO, CANADA. There is some evidence from animal experiments that antidepressants may promote breast cancer tumors. One case-control study found an association between the use of tricyclic antidepressants AND breast cancer risk, but the data concerning SSRIs (selective serotonin reuptake inhibitors) is inconsistent. Researchers at the University of Toronto now confirm that long-term use of tricylic antidepressants is indeed associated with an increased incidence of breast cancer. The study involved 700 women with breast cancer (aged 25 to 74 years) AND 700 age-matched controls. A comparison of the use of antidepressants between the cases AND the controls found no significant overall differences in breast cancer risks. However, when evaluating the data in detail the researchers discovered that women who had used tricyclic antidepressants for 25 months OR more had twice the risk of developing breast cancer as had women who had not used these antidepressants. They also noted that women who had used the SSRI antidepressant paroxetine (Paxil) for more than two weeks had a seven times greater risk of breast cancer even when other possible risk factors were fully accounted for. The researchers caution that the number of women using paroxetine was quite small AND recommend larger trials to confirm their initial finding. They do point out though that paroxetine stimulates prolactin secretion AND is a potent inhibitor of the cytochrome P450 2D6 enzyme, both factors in an increased breast cancer risk. Cotterchio, Michelle, et al. Antidepressant medication use AND breast cancer risk. American Journal of Epidemiology, Vol. 151, May 15, 2000, pp. 951-57

בדקי את הקישור הבא : http://www.yourhealthbase.com/breast_cancer_risk_factors.html More on breast cancer AND paroxetine TORONTO, CANADA. In the August 2000 issue of IHN we reported on the findings of Dr. Michelle Cotterchio AND colleagues (New England Journal of Medicine, Vol. 342, June 29, 2000, p. 2003) to the effect that the use of the antidepressant paroxetine (Paxil) may increase the risk of breast cancer by a factor of seven. If confirmed these findings would almost certainly lead to a caution against prescribing paroxetine to women. Not surprisingly, Dr. Cotterchio’s report has caused a considerable stir within the medical AND pharmaceutical communities. The December issue of the American Journal of Epidemiology contains two letters (one from the manufacturer of paroxetine, SmithKline Beecham Pharmaceuticals) that question the validity of Dr. Cotterchio’s conclusions. The authors of both letters point out that the number of cases of possible paroxetine-related breast cancer was small (9 cases AND 1 control) AND the SmithKline Beecham letter also makes the observation that most of the patients who had taken paroxetine had previously been exposed to fluoxetine (Prozac). Dr. Cotterchio replies that her report concluded that “use of paroxetine may be associated with a substantial increase in breast cancer” AND that future studies would be required in order to confirm this. She also reiterates that, while she AND her team do not suggest that paroxetine is a carcinogen (cancer initiator), they do believe that it could well be a promoter of breast cancer. She points out that animal studies support the hypothesis that antidepressants may be tumor promoters. It would seem that the final conclusion on the possible relationship between paroxetine AND breast cancer must await the completion of the larger study. Antidepressant medication use AND breast cancer risk. American Journal of Epidemiology, Vol. 152, December 1, 2000, pp. 1104-05 (letters to the editor) Antidepressants AND breast cancer TORONTO, CANADA. There is some evidence from animal experiments that antidepressants may promote breast cancer tumors. One case-control study found an association between the use of tricyclic antidepressants AND breast cancer risk, but the data concerning SSRIs (selective serotonin reuptake inhibitors) is inconsistent. Researchers at the University of Toronto now confirm that long-term use of tricylic antidepressants is indeed associated with an increased incidence of breast cancer. The study involved 700 women with breast cancer (aged 25 to 74 years) AND 700 age-matched controls. A comparison of the use of antidepressants between the cases AND the controls found no significant overall differences in breast cancer risks. However, when evaluating the data in detail the researchers discovered that women who had used tricyclic antidepressants for 25 months OR more had twice the risk of developing breast cancer as had women who had not used these antidepressants. They also noted that women who had used the SSRI antidepressant paroxetine (Paxil) for more than two weeks had a seven times greater risk of breast cancer even when other possible risk factors were fully accounted for. The researchers caution that the number of women using paroxetine was quite small AND recommend larger trials to confirm their initial finding. They do point out though that paroxetine stimulates prolactin secretion AND is a potent inhibitor of the cytochrome P450 2D6 enzyme, both factors in an increased breast cancer risk. Cotterchio, Michelle, et al. Antidepressant medication use AND breast cancer risk. American Journal of Epidemiology, Vol. 151, May 15, 2000, pp. 951-57

בדקי את הקישור הבא : http://www.yourhealthbase.com/breast_cancer_risk_factors.html More on breast cancer AND paroxetine TORONTO, CANADA. In the August 2000 issue of IHN we reported on the findings of Dr. Michelle Cotterchio AND colleagues (New England Journal of Medicine, Vol. 342, June 29, 2000, p. 2003) to the effect that the use of the antidepressant paroxetine (Paxil) may increase the risk of breast cancer by a factor of seven. If confirmed these findings would almost certainly lead to a caution against prescribing paroxetine to women. Not surprisingly, Dr. Cotterchio’s report has caused a considerable stir within the medical AND pharmaceutical communities. The December issue of the American Journal of Epidemiology contains two letters (one from the manufacturer of paroxetine, SmithKline Beecham Pharmaceuticals) that question the validity of Dr. Cotterchio’s conclusions. The authors of both letters point out that the number of cases of possible paroxetine-related breast cancer was small (9 cases AND 1 control) AND the SmithKline Beecham letter also makes the observation that most of the patients who had taken paroxetine had previously been exposed to fluoxetine (Prozac). Dr. Cotterchio replies that her report concluded that “use of paroxetine may be associated with a substantial increase in breast cancer” AND that future studies would be required in order to confirm this. She also reiterates that, while she AND her team do not suggest that paroxetine is a carcinogen (cancer initiator), they do believe that it could well be a promoter of breast cancer. She points out that animal studies support the hypothesis that antidepressants may be tumor promoters. It would seem that the final conclusion on the possible relationship between paroxetine AND breast cancer must await the completion of the larger study. Antidepressant medication use AND breast cancer risk. American Journal of Epidemiology, Vol. 152, December 1, 2000, pp. 1104-05 (letters to the editor) Antidepressants AND breast cancer TORONTO, CANADA. There is some evidence from animal experiments that antidepressants may promote breast cancer tumors. One case-control study found an association between the use of tricyclic antidepressants AND breast cancer risk, but the data concerning SSRIs (selective serotonin reuptake inhibitors) is inconsistent. Researchers at the University of Toronto now confirm that long-term use of tricylic antidepressants is indeed associated with an increased incidence of breast cancer. The study involved 700 women with breast cancer (aged 25 to 74 years) AND 700 age-matched controls. A comparison of the use of antidepressants between the cases AND the controls found no significant overall differences in breast cancer risks. However, when evaluating the data in detail the researchers discovered that women who had used tricyclic antidepressants for 25 months OR more had twice the risk of developing breast cancer as had women who had not used these antidepressants. They also noted that women who had used the SSRI antidepressant paroxetine (Paxil) for more than two weeks had a seven times greater risk of breast cancer even when other possible risk factors were fully accounted for. The researchers caution that the number of women using paroxetine was quite small AND recommend larger trials to confirm their initial finding. They do point out though that paroxetine stimulates prolactin secretion AND is a potent inhibitor of the cytochrome P450 2D6 enzyme, both factors in an increased breast cancer risk. Cotterchio, Michelle, et al. Antidepressant medication use AND breast cancer risk. American Journal of Epidemiology, Vol. 151, May 15, 2000, pp. 951-57